amoxicillin-clavulanate
DrugAmoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
Other names: Clavurion
NCT Number: NCT01244581
The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry performed by families and study physicians.
Looking for future studies?
Notify MeUp to 16 year
All sexes
Interventional
Phase 3
Department of Pediatrics, Oulu University Hospital, Oulu, Finland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
Other names: Clavurion
Placebo mixture in two daily doses for 7 days
Time frame: Within 60 days
Disappearance of middle ear effusion is defined as the first day of receiving a normal tympanogram (A-curve) in tympanometry.
Time frame: Within 60 days
University of Oulu
Other
Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04752891
Ear Diseases, Infections
Nice, France
View Trial DetailsNCT05605262
Ear Diseases, Infections
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT07721610
Ear Diseases, Hearing Disorders
Roma, Italy
View Trial DetailsNCT07242001
Ear Diseases, OTITIS MEDIA WITH EFFUSION
Jakarta Pusat, DKI Jakarta, Indonesia
View Trial Details